Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 53, Issue 7, Pages 557-573Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2008.10.041
Keywords
heart; failure; decompensated; acute; syndromes
Categories
Funding
- Abbott
- Astellas
- Bayer
- AstraZeneca
- Corthera
- Debiopharm
- Errekappa Terapeutici
- EKR Therapeutics
- GlaxoSmithKline
- Johnson Johnson
- Medtronic
- Merck
- Nile
- Novartis
- Otsuka
- PeriCor
- PDL BioPharma
- Scios Inc
- Solvay Pharmaceuticals
- Sigma-Tau
- Biogen Idec
- Palatin Technologies
Ask authors/readers for more resources
Heart failure resulting in hospitalization represents a significant and growing health care burden. Heterogeneity characterizes this group in terms of mode of presentation, pathophysiology, and prognosis. The vast majority of patients symptomatically improve during hospitalization; however, their early post-discharge rehospitalization and mortality rates continue to be high. Worsening signs and symptoms, neurohormonal, and renal abnormalities occurring soon after discharge may contribute to these high post-discharge event rates. Currently available assessment modalities combined with recent advances in cardiovascular therapies provide present-day opportunities to improve post-discharge outcomes. Further investigation into pathophysiologic targets and novel approaches to clinical trial design are needed. Improving post-discharge outcomes is the single most important goal in the management of acute heart failure syndromes. (J Am Coll Cardiol 2009; 53: 557-73) (C) 2009 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available